Molecular Partners starts Phase 1/2a trial of DLL3-targeting radiotherapy MP0712 in SCLC, neuroendocrine tumors
PUBT · 5d ago
Share
Listen to the news
- Molecular Partners flagged a U.S. Phase 1/2a study of DLL3-targeting radiotherapy MP0712, with patient dosing underway in the first cohort.
- Initial clinical data are expected in 2026, with trial-in-progress posters scheduled for ASCO on May 30 and SNMMI on June 2.
- Earlier first-patient imaging and dosimetry results were presented in January 2026, supporting continued clinical development of the program.
- The trial aims to establish safety and set a recommended Phase 2 dose in small cell lung cancer and other DLL3-expressing solid tumors.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Molecular Partners AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605300800PRIMZONEFULLFEED9728885) on May 30, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved